drugset / Trial / NCT04346862

Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease

NCT04346862

Phase 4 Unknown 636 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of Acetyl-L-carnitine in patient with Mild Cognitive Impairment associated with chronic cerebrovascular disease.

Timeline

Start
2016-01-26
Primary completion
2020-06-30
Completion
2020-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetylcarnitine Small molecule 500 mg Oral